Therefore, our results suggest that apatinib may partially restore the activation of T cells by targeting the VEGFR2/PD-L1 signaling pathway in tumor cells, thus exerting its tumor suppressive effect, which was likewise enhanced by the combined application of CPT. This evidence concerns the gene KDR and neoplasm.